Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data

Diabetic Medicine : a Journal of the British Diabetic Association
K H HaH C Kim

Abstract

To compare the risks of cardiovascular disease (CVD) and all-cause mortality associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP4i) and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy in people with Type 2 diabetes. We identified 40 263 individuals who used SU (n = 11 582), DPP4i (n = 26 623) or TZD (n = 2058) in addition to MET between January 2013 and June 2015 from the database of the Korean National Health Insurance, the single-payer healthcare system in South Korea. Cox proportional hazard models were used to estimate hazard ratios for major CVD event (coronary artery disease, heart failure, stroke or transient ischaemic attack) development and all-cause mortality by second-line anti-diabetes medication type. Age, sex, duration of MET monotherapy, calendar year and comorbid conditions were adjusted as potential confounders. The observed numbers of CVD events (total observed person-time) were 485 (18 778 person-years) for MET + SU, 744 (40 374 person-years) for MET + DPP4i and 60 (3014 person-years) for MET + TZD users. Compared with MET + SU users, the fully adjusted hazard ratios for CVD events were 0.79 [95% confidence interval (CI): 0.71-0.89] for MET + DPP4i users and 0.85 ...Continue Reading

References

Jul 20, 2007·Biometrical Journal. Biometrische Zeitschrift·Douglas E Schaubel, Guanghui Wei
Sep 13, 2007·JAMA : the Journal of the American Medical Association·A Michael LincoffSteven E Nissen
Mar 13, 2010·Expert Review of Cardiovascular Therapy·Christina L Aquilante
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
Jun 15, 2011·Vascular Pharmacology·Gian Paolo Fadini, Angelo Avogaro
Mar 21, 2012·Pharmacoepidemiology and Drug Safety·Christianne L RoumieMarie R Griffin
Apr 19, 2013·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
May 9, 2013·Nature Medicine·Maryam AhmadianRonald M Evans
Aug 1, 2013·BMJ : British Medical Journal·Atsushi GotoMitsuhiko Noda
Aug 31, 2013·Diabetes & Metabolism Journal·Ie Byung ParkSei Hyun Baik
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Dec 4, 2013·Annals of Internal Medicine·Caroline K KramerRavi Retnakaran
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jul 8, 2015·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh

❮ Previous
Next ❯

Citations

Mar 14, 2020·Diabetes, Obesity & Metabolism·Yun ShenGang Hu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.